LLY logo Eli Lilly and Company +
Eli Lilly and Company
+

Eli Lilly and Company Overview

Company: Eli Lilly and Company
CEO: David A. Ricks
Founded: 1876
Symbol: LLY
Exchange: NYSE
Industry: Drug Manufacturers - General
Sector: Healthcare
About

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals; AbCellera Biologics; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics; Kumquat Biosciences; Entos Pharmaceuticals; and Foghorn Therapeutics Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Continue reading...

Eli Lilly and Company (LLY)

  • Stock Price
  • Volume
+810.29 +416.32%
Past 5 Years
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • 10Y
  • ALL

Revenue

Eli Lilly and Company annual revenue was $65.18 B in 2025.

Net Income

Eli Lilly and Company annual net income was $20.64 B in 2025.

Employees

Eli Lilly and Company annual employee count was 50,000 in 2025.

Revenue by Segment

Eli Lilly and Company’s revenue by segment: Collaboration and Other Revenue: $4.22 B and Product: $60.96 B in 2025.

Revenue by Region

Eli Lilly and Company’s revenue by region: CHINA: $1.95 B, Europe: $11.56 B, JAPAN: $2.13 B, Non-US: $6.06 B and UNITED STATES: $43.48 B in 2025.

Executive Salary

David A. Ricks Chair, President, and Chief Executive Officer, at Eli...

Revenue per Employee

Eli Lilly and Company revenue per employee was $1.30 M in 2025.

Profit per Employee

Eli Lilly and Company profit per employee was $412.77 K in 2025.

Income Statement

Operating Income

Eli Lilly and Company annual operating income was $29.70 B in 2025.

Research & Development

Eli Lilly and Company annual research & development expense was $13.34 B in 2025.

Tax Rate (%)

Eli Lilly and Company annual Tax Rate was 20.00% in 2025.

Assets & Liabilities | Cash Flow

Total Assets

Eli Lilly and Company annual total assets was $112.48 B in 2025.

Total Liabilities

Eli Lilly and Company annual total liabilities was $85.94 B in 2025.

Capital Expenditure

Eli Lilly and Company annual capital expenditures was -$7.84 B in 2025.

Ratios

Return on Equity (ROE)

Eli Lilly and Company annual return on equity(ROE) was 0.00% in 2025.

Return on Assets (ROA)

Eli Lilly and Company annual return on assets(ROA) was 0.00% in 2025.

Debt to Equity

Eli Lilly and Company annual debt to equity was 160.18% in 2025.

Profitability

Gross Profit Margin (%)

Eli Lilly and Company annual gross profit margin was 83.79% in 2025.

Operating Income Margin (%)

Eli Lilly and Company annual operating income margin was 45.56% in 2025.

Net Income Margin (%)

Eli Lilly and Company annual net income margin was 31.66% in 2025.

Earning Per Share

Eli Lilly and Company annual earning per share was $22.98 in 2025.

EBITDA

Eli Lilly and Company annual EBITDA was $27.94 B in 2025.

Free Cash Flow (FCF)

Eli Lilly and Company annual free cash flow(FCF) was $8.97 B in 2025.

Valuation

Enterprise value

Eli Lilly and Company annual enterprise value was - in 2025.

Enterprise value to Revenue

Eli Lilly and Company annual enterprise value to revenue was 0.00 in 2025.

Enterprise value to EBITDA

Eli Lilly and Company annual enterprise value to EBITDA was 0.00 in 2025.

Competitors’ Revenue

Frequently Asked Questions

When was Eli Lilly and Company founded?

Eli Lilly and Company was founded on 1876, which makes the company 150 years old.

Sign up for free to view

Who is the CEO of Eli Lilly and Company?

David A. Ricks is the CEO of Eli Lilly and Company.

What industry and sector is Eli Lilly and Company in?

Eli Lilly and Company operates in the Drug Manufacturers - General industry and the Healthcare sector.

What are Eli Lilly and Company's CIK, SIC, and ISIN codes?

  • CIK (Central Index Key): 0000059478
  • SIC (Standard Industrial Classification): 2834
  • ISIN (International Securities Identification Number): US5324571083

Sign up for free to view

How many employees does Eli Lilly and Company have?

Eli Lilly and Company has 50,000 employees.

What is the revenue of Eli Lilly and Company?

In fiscal year 2025, Eli Lilly and Company generated a revenue of $65.18 Billion.

What is the net income of Eli Lilly and Company?

In fiscal year 2025, Eli Lilly and Company reported a net income of $20.64 Billion.

What is Eli Lilly and Company's biggest product segment?

Product is Eli Lilly and Company's biggest product segment, representing 93.52% of its total revenue.

When was Eli Lilly and Company listed on the stock exchange?

Eli Lilly and Company went public on Jun 1, 1972, through its Initial Public Offering (IPO), and it has been 53 years since then.

Sign up for free to view

What is the ticker symbol of Eli Lilly and Company, and where is it listed?

Eli Lilly and Company's ticker symbol is LLY, and the company is listed on the NYSE stock market exchange.

What is Eli Lilly and Company's current stock price?

Eli Lilly and Company's current stock price is $1.00 K as of May 16, 2026.

What is Eli Lilly and Company's market capitalization?

As of , Eli Lilly and Company's market cap is .

What is Eli Lilly and Company's ranking in the world?

Ranked #1among 2,804 companies based on market cap.

Who are the top competitors of Eli Lilly and Company?

Competitors of Eli Lilly and Company include Johnson & Johnson, AbbVie and Merck & Co., and more.

Related company

Submit feedback to Bullfincher